US 12,168,684 B2
Antibody mimetic capable of being activated reversibly and uses thereof
Won Do Heo, Daejeon (KR); Yun Ju Lee, Daejeon (KR); Daseuli Yu, Sejong (KR); and Byung Ouk Park, Daejeon (KR)
Assigned to INSTITUTE FOR BASIC SCIENCE, Daejeon (KR)
Filed by INSTITUTE FOR BASIC SCIENCE, Daejeon (KR)
Filed on Sep. 7, 2021, as Appl. No. 17/468,590.
Application 17/468,590 is a division of application No. 15/742,874, granted, now 11,155,604, previously published as PCT/KR2016/015061, filed on Dec. 21, 2016.
Claims priority of application No. 10-2016-0013121 (KR), filed on Feb. 2, 2016.
Prior Publication US 2022/0002388 A1, Jan. 6, 2022
Int. Cl. C07K 16/00 (2006.01); C07K 14/00 (2006.01); C07K 16/14 (2006.01); C07K 16/18 (2006.01)
CPC C07K 16/00 (2013.01) [C07K 14/00 (2013.01); C07K 16/14 (2013.01); C07K 16/18 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01); C07K 2319/07 (2013.01); C07K 2319/60 (2013.01); C07K 2319/70 (2013.01)] 3 Claims
 
1. A composition comprising a first polynucleotide encoding a first fusion protein comprising a first antibody fragment fused to a light-induced dimerization protein, and a second polynucleotide encoding a second fusion protein comprising a second antibody fragment fused to a light-induced dimerization partner protein capable of binding of light-induced dimerization protein by light irradiation, wherein binding of light-induced dimerization protein to the light-induced dimerization partner protein induced by light producing a light-activatable antibody,
wherein when the antibody is scFv, the first antibody fragment is VL, the second antibody fragment is VH,
wherein when the antibody if Fab, the first antibody fragment is VL-CL, the second antibody fragment is VH-CH1, or
wherein the antibody is VH, the antibody fragments are cleaved at a non-CDR loop region of VH,
wherein the light induced dimerization protein is CIB (cryptochrome-interacting basic-helix-loop-helix protein), CIBN (N-terminal region of the CIB, PhyB (phytochrome A), PIF (phytochrome interacting protein), FKF1 (Flavin-binding, Kelch repeat, F-box protein), GIGANTEA, CRY (chryptochrome protein), PHR (N-terminal regioin of CRY), nMag (negative Magnet protein), or pMag (positive Magnet protein);
wherein the light-inducted idmerization protein is CRY or PHR, the light-induced dimerization partner protein is CIB or CIBN;
wherein the light-induced dimerization protein is PIF, the light-induced dimerization partner protein in PhyB;
wherein the light-inducted dimerization protein is GIGANTEA, the light-induced dimerization partner protein in KFK1;
wherein the light-induced dimerization protein is CIB or CIBN, the light-induced dimerization partner protein is CRY or CIBN;
wherein the light-induced dimerization protein is PhyB, the light-induced dimerization partner protein in PIF;
wherein the light-induced dimerization protein is FKF1, the light-induced dimerization partner protein in GIGANTEA;
wherein the light-induced dimerization protein is pMag, the light-induced dimerization partner protein in nMag; or
wherein the light-induced dimerization protein is nMag, the light-induced dimerization partner protein in pMag.